| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8680579 | Alzheimer's & Dementia: Translational Research & Clinical Interventions | 2017 | 18 Pages |
Abstract
The AD drug development pipeline has 105 agents divided among phase I, phase II, and phase III. The trials include a wide range of clinical trial populations, many mechanisms of action, and require a substantial number of clinical trial participants. Biomarkers are increasingly used in patient identification and as outcome measures, particularly in trials of DMTs.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Jeffrey Cummings, Garam Lee, Travis Mortsdorf, Aaron Ritter, Kate Zhong,